Compare RJET & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJET | DBVT |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | France |
| Employees | 8400 | 90 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.0M | 948.8M |
| IPO Year | 2009 | 2014 |
| Metric | RJET | DBVT |
|---|---|---|
| Price | $18.79 | $14.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.04 |
| AVG Volume (30 Days) | 91.0K | ★ 330.6K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.43 | 10.26 |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $1,676,500,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | $14.90 | ★ N/A |
| Revenue Growth | 13.74 | ★ 35.77 |
| 52 Week Low | $15.37 | $8.80 |
| 52 Week High | $26.70 | $26.19 |
| Indicator | RJET | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 55.70 |
| Support Level | $18.40 | $12.75 |
| Resistance Level | $19.55 | $17.43 |
| Average True Range (ATR) | 0.77 | 0.65 |
| MACD | -0.24 | 0.17 |
| Stochastic Oscillator | 30.41 | 97.16 |
Republic Airways Holdings Inc is a regional airline mainly in North America. The company provides scheduled passenger service through its mainline partnerships with American Airlines, Delta Air Lines, and United Airlines. Republic offers scheduled passenger service on several daily flights to various cities in the United States, Canada, Mexico, and the Caribbean. It exclusively operates the dual-class Embraer E170/175 family of aircraft, and provides its services under the American Eagle, Delta Connection, or United Express brands. The company is organized and operates as one operating and reportable segment: regional airline services.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.